Self-stimulation of the MFB following parabrachial lesions.

Physiol Behav

Department of Psychology, Concordia University, Montreal, Quebec, Canada.

Published: September 1995

It has been reported previously that the parabrachial region supports robust self-stimulation. In the present study, we determined whether lesions of the parabrachial nucleus (PBN) influence the rewarding effect of medial forebrain bundle (MFB) stimulation. In 10 rats, stimulation electrodes were aimed at the lateral hypothalamus and/or ventral tegmental area and a lesioning electrode aimed at the PBN. Rate-frequency curves were collected at each of three stimulation currents at each electrode, before and after lesioning. Four rats showed virtually no change in the frequency required to sustain half-maximal performance following lesioning, and two showed some postlesion decreases. Only two rats showed substantial postlesion increases in required frequency; the lesions in these subjects damaged the region ventral to the superior cerebellar peduncle, just caudal to the decussation of the peduncle, but spared the PBN. Thus, the reward effectiveness of MFB stimulation does not appear to be altered substantially following PBN lesions but may decrease following damage to the neighboring pedunculopontine region.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0031-9384(95)00092-wDOI Listing

Publication Analysis

Top Keywords

mfb stimulation
8
self-stimulation mfb
4
mfb parabrachial
4
lesions
4
parabrachial lesions
4
lesions reported
4
reported parabrachial
4
parabrachial region
4
region supports
4
supports robust
4

Similar Publications

Background: Post-traumatic stress disorder (PTSD) causes intrusive symptoms and avoidance behaviours due to dysregulation in various brain regions, including the hippocampus. Deep brain stimulation (DBS) shows promise for refractory PTSD cases. In rodents, DBS improves fear extinction and reduces anxiety-like behaviours, but its effects on active-avoidance extinction remain unexplored.

View Article and Find Full Text PDF

Chronic in vivo sequelae of repetitive acute mfb-DBS on accumbal dopamine and midbrain neuronal activity.

J Neurochem

January 2025

Laboratory of Stereotaxy and Interventional Neurosciences (SIN), Department of Stereotactic and Functional Neurosurgery, Medical Center, -University of Freiburg, Freiburg im Breisgau, Germany.

Article Synopsis
  • * Research includes studying dopamine (DA) signaling over 8 weeks with different MFB-DBS parameters in both active and non-active animals, revealing that higher stimulation frequency boosts DA release and may explain the treatment's long-term effectiveness.
  • * Results indicate that changes in DA response are influenced by stimulation frequency and duration, with notable variations in DA signaling patterns suggesting complex interactions within the brain's circuits during treatment.
View Article and Find Full Text PDF
Article Synopsis
  • OnabotulinumtoxinA (onabotA) is believed to help reduce migraine symptoms by blocking certain nerve pathways during their activation process in the brain and spinal cord.
  • A study was conducted on anesthetized rats to observe how onabotA injections affected the activation of specific nerve cells in response to a triggering event called cortical spreading depression (CSD).
  • Results showed that onabotA significantly reduced activation in wide-dynamic range neurons, preventing enhanced responses to mechanical stimuli, indicating its effectiveness in moderating migraine-related nerve sensitivity.
View Article and Find Full Text PDF

The aim of the study is to understand the rationale behind the application of deep brain stimulation (DBS) in the treatment of depression. Male Wistar rats, rendered depressive with chronic unpredictable mild stress (CUMS) were implanted with electrode in the lateral hypothalamus-medial forebrain bundle (LH-MFB) and subjected to deep brain stimulation (DBS) for 4 h each day for 14 days. DBS rats, as well as controls, were screened for a range of parameters indicative of depressive state.

View Article and Find Full Text PDF

Depression and anxiety are prevalent neuropsychiatric conditions among patients with Parkinson's disease (PD), which may manifest prior to motor symptoms. As levodopa, a prominent treatment for PD motor symptoms, provides few benefits for mood-related abnormalities, tackling non-motor symptoms is particularly important. AdipoRon (Ad), an adiponectin agonist, has demonstrated neuroprotective effects by suppressing neuroinflammatory responses and activating the AMPK/Sirt-1 signaling pathway.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!